196 related articles for article (PubMed ID: 36900250)
1. A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma.
Villanueva G; Guscott M; Schaiquevich P; Sampor C; Combs R; Tentoni N; Hwang M; Lowe J; Howard S
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900250
[TBL] [Abstract][Full Text] [Related]
2. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
3. Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort.
Yerram P; Reiss SN; Modelevsky L; Schaff L; Reiner AS; Panageas KS; Grommes C
Ann Lymphoma; 2023 Feb; 7():. PubMed ID: 37067886
[TBL] [Abstract][Full Text] [Related]
4. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
6. Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome.
Singh C; Jain A; Takkar A; Agarwal A; Rohilla M; Lad D; Khadwal A; Basher R; Radotra BD; Bal A; Das A; Gupta V; Lal V; Varma S; Malhotra P; Prakash G
Indian J Hematol Blood Transfus; 2022 Jan; 38(1):68-77. PubMed ID: 35125713
[TBL] [Abstract][Full Text] [Related]
7. [Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab].
Shiota Y; Dobashi N; Ito Y; Hosoba R; Yamauchi H; Ishii H; Nakano A; Fukushima R; Ohba R; Yahagi Y; Usui N; Yano S
Rinsho Ketsueki; 2019; 60(2):87-92. PubMed ID: 30842385
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
10. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series.
Seidel S; Kowalski T; Margold M; Baraniskin A; Schroers R; Martus P; Schlegel U
Ther Adv Neurol Disord; 2020; 13():1756286420951087. PubMed ID: 33101460
[TBL] [Abstract][Full Text] [Related]
11. Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome.
Seidel S; Margold M; Kowalski T; Baraniskin A; Schroers R; Korfel A; Thiel E; Weller M; Martus P; Schlegel U
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208229
[TBL] [Abstract][Full Text] [Related]
12. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
13. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
14. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
15. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Goldschmidt N; Horowitz NA; Heffes V; Darawshy F; Mashiach T; Shaulov A; Gatt ME; Dann EJ
Leuk Lymphoma; 2019 Aug; 60(8):1890-1898. PubMed ID: 30689468
[TBL] [Abstract][Full Text] [Related]
16. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma.
Haran A; Even-Zohar NG; Haran M; Lebel E; Aumann S; Shaulov A; Gatt M; Nachmias B
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):187-193.e1. PubMed ID: 38008594
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.
Kim J; Kim TG; Lee HW; Kim SH; Park JE; Lee M; Kim YZ
Curr Oncol; 2021 Nov; 28(6):4655-4672. PubMed ID: 34898570
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
19. Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences.
Patekar M; Adhikari N; Biswas A; Raina V; Kumar L; Mohanti BK; Gogia A; Sharma A; Batra A; Bakhshi S; Garg A; Thulkar S; Sharma MC; Vishnubhatla S; Baghmar S; Sahoo RK
J Glob Oncol; 2019 Feb; 5():1-9. PubMed ID: 30811305
[TBL] [Abstract][Full Text] [Related]
20. Review of rituximab in primary CNS lymphoma.
Singh PK; Pan E
J Neurol Sci; 2020 Mar; 410():116649. PubMed ID: 31901591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
